Clinical Trials | December 13, 2022
Moderna and Merck announce personalized mRNA cancer vaccine
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Expressed happiness that more than 30 countries of the world have given recognition to Ayurveda as a traditional system of medicine
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
35 million mosquito nets supplied to countries in sub-Saharan Africa through partners
The use of procalcitonin testing for sepsis management is highest in the US
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
Subscribe To Our Newsletter & Stay Updated
